Enzyme analysis often cannot accurately determine if an individual is a carrier for an MPS disorder, because the enzyme levels in individuals who are not carriers overlaps the enzyme levels seen in those individuals who are carrier for MPS.
Minimum Performance Standards (MPS) are evaluated following every Summer National Senior Games to establish a method whereby an athlete can qualify for the Summer Games by meeting or exceeding the standard.
Unlike the other MPS conditions, MPS II is inherited in an X-linked recessive manner, which means that the gene causing the condition is located on the X chromosome, one of the two sex chromosomes.
Prenatal testing can also diagnose MPS in the fetus, but this testing is normally done only when there is some reason to expect to find the disorder (e.g. family history of the disease).
For some of the MPS diseases, biochemical tests may be able to identify healthy individuals who are carriers of the defective gene, allowing them to make informed reproductive decisions.
Hurler-Scheie syndrome an intermediate form of MPS I, meaning that the symptoms are not as severe as those in individuals who have MPS I H but not as mild as those in MPS I S.
Once a couple has had a child with MPS, prenatal testing is available to them to help determine if another fetus is affected with the same MPS as their previous other child.
Many children with MPS III develop seizures, sleeplessness, thicker skin, joint contractures, enlarged tongues, cardiomyopathy, behavior problems, and mental retardation.
Mucopolysaccharidosis (MPS) is a general term for many different related inherited disorders that are caused by the accumulation of mucopolysaccharides in body tissues.
For those types of MPS, bone marrow transplantation has sometimes helped slow down the progression or reverse some of symptoms of the disorder in some children.